Literature DB >> 34283254

Enhancer reprogramming in PRC2-deficient malignant peripheral nerve sheath tumors induces a targetable de-differentiated state.

Veena Kochat1,2, Ayush T Raman2,3,4, Sharon M Landers1, Ming Tang2,4, Jonathan Schulz2, Christopher Terranova2, Jace P Landry1,5, Angela D Bhalla1, Hannah C Beird2, Chia-Chin Wu2, Yingda Jiang2,6, Xizeng Mao2, Rossana Lazcano7, Swati Gite7, Davis R Ingram7, Min Yi1, Jianhua Zhang2, Emily Z Keung1, Christopher P Scally1, Christina L Roland1, Kelly K Hunt1, Barry W Feig1, P Andrew Futreal2, Patrick Hwu8,9, Wei-Lien Wang7, Alexander J Lazar7, John M Slopis10, Heather Wilson-Robles11, Dominique J Wiener12, Ian E McCutcheon13, Brandan Wustefeld-Janssens11,14, Kunal Rai15,16, Keila E Torres17,18,19.   

Abstract

Malignant peripheral nerve sheath tumors (MPNSTs) are soft tissue sarcomas that frequently harbor genetic alterations in polycomb repressor complex 2 (PRC2) components-SUZ12 and EED. Here, we show that PRC2 loss confers a dedifferentiated early neural-crest phenotype which is exclusive to PRC2-mutant MPNSTs and not a feature of neurofibromas. Neural crest phenotype in PRC2 mutant MPNSTs was validated via cross-species comparative analysis using spontaneous and transgenic MPNST models. Systematic chromatin state profiling of the MPNST cells showed extensive epigenomic reprogramming or chromatin states associated with PRC2 loss and identified gains of active enhancer states/super-enhancers on early neural crest regulators in PRC2-mutant conditions around genomic loci that harbored repressed/poised states in PRC2-WT MPNST cells. Consistently, inverse correlation between H3K27me3 loss and H3K27Ac gain was noted in MPNSTs. Epigenetic editing experiments established functional roles for enhancer gains on DLX5-a key regulator of neural crest phenotype. Consistently, blockade of enhancer activity by bromodomain inhibitors specifically suppressed this neural crest phenotype and tumor burden in PRC2-mutant PDXs. Together, these findings reveal accumulation of dedifferentiated neural crest like state in PRC2-mutant MPNSTs that can be targeted by enhancer blockade.
© 2021. This is a U.S. government work and not under copyright protection in the U.S.; foreign copyright protection may apply.

Entities:  

Keywords:  BRD4 inhibitor; Enhancer activation; Epigenomic reprogramming; Malignant peripheral nerve sheath tumor; Neural-crest phenotype; Polycomb repressor complex 2

Mesh:

Substances:

Year:  2021        PMID: 34283254     DOI: 10.1007/s00401-021-02341-z

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  80 in total

1.  Loss of H3K27 tri-methylation is a diagnostic marker for malignant peripheral nerve sheath tumors and an indicator for an inferior survival.

Authors:  Arjen Hg Cleven; Ghadah A Al Sannaa; Inge Briaire-de Bruijn; Davis R Ingram; Matt van de Rijn; Brian P Rubin; Maurits W de Vries; Kelsey L Watson; Kelia E Torres; Wei-Lien Wang; Sjoerd G van Duinen; Pancras Cw Hogendoorn; Alexander J Lazar; Judith Vmg Bovée
Journal:  Mod Pathol       Date:  2016-09       Impact factor: 7.842

2.  Reconstruction of enhancer-target networks in 935 samples of human primary cells, tissues and cell lines.

Authors:  Qin Cao; Christine Anyansi; Xihao Hu; Liangliang Xu; Lei Xiong; Wenshu Tang; Myth T S Mok; Chao Cheng; Xiaodan Fan; Mark Gerstein; Alfred S L Cheng; Kevin Y Yip
Journal:  Nat Genet       Date:  2017-09-04       Impact factor: 38.330

3.  SOX9 expression increases with malignant potential in tumors from patients with neurofibromatosis 1 and is not correlated to desert hedgehog.

Authors:  Amélie Carbonnelle-Puscian; Valérie Vidal; Ingrid Laurendeau; Laurence Valeyrie-Allanore; Dominique Vidaud; Ivan Bièche; Karen Leroy; Laurent Lantieri; Pierre Wolkenstein; Andreas Schedl; Nicolas Ortonne
Journal:  Hum Pathol       Date:  2010-12-28       Impact factor: 3.466

4.  Cells of origin in the embryonic nerve roots for NF1-associated plexiform neurofibroma.

Authors:  Zhiguo Chen; Chiachi Liu; Amish J Patel; Chung-Ping Liao; Yong Wang; Lu Q Le
Journal:  Cancer Cell       Date:  2014-10-30       Impact factor: 31.743

5.  ZIC1 overexpression is oncogenic in liposarcoma.

Authors:  Elliott Brill; Ryan Gobble; Christina Angeles; Mariana Lagos-Quintana; Aimee Crago; Bernadette Laxa; Penelope Decarolis; Lei Zhang; Cristina Antonescu; Nicholas D Socci; Barry S Taylor; Chris Sander; Andrew Koff; Samuel Singer
Journal:  Cancer Res       Date:  2010-08-16       Impact factor: 12.701

6.  Discovery of pan-ErbB inhibitors protecting from SARS-CoV-2 replication, inflammation, and lung injury by a drug repurposing screen.

Authors:  Sirle Saul; Marwah Karim; Pei-Tzu Huang; Luca Ghita; Winston Chiu; Sathish Kumar; Nishank Bhalla; Pieter Leyssen; Courtney A Cohen; Kathleen Huie; Courtney Tindle; Mamdouh Sibai; Benjamin A Pinsky; Soumita Das; Pradipta Ghosh; John M Dye; David E Solow-Cordero; Jing Jin; Dirk Jochmans; Johan Neyts; Aarthi Narayanan; Steven De Jonghe; Shirit Einav
Journal:  bioRxiv       Date:  2021-06-15

Review 7.  Assembling neural crest regulatory circuits into a gene regulatory network.

Authors:  Paola Betancur; Marianne Bronner-Fraser; Tatjana Sauka-Spengler
Journal:  Annu Rev Cell Dev Biol       Date:  2010       Impact factor: 13.827

8.  An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors.

Authors:  Ittai Ben-Porath; Matthew W Thomson; Vincent J Carey; Ruping Ge; George W Bell; Aviv Regev; Robert A Weinberg
Journal:  Nat Genet       Date:  2008-05       Impact factor: 38.330

9.  UpSetR: an R package for the visualization of intersecting sets and their properties.

Authors:  Jake R Conway; Alexander Lex; Nils Gehlenborg
Journal:  Bioinformatics       Date:  2017-09-15       Impact factor: 6.937

10.  Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples.

Authors:  Kristian Cibulskis; Michael S Lawrence; Scott L Carter; Andrey Sivachenko; David Jaffe; Carrie Sougnez; Stacey Gabriel; Matthew Meyerson; Eric S Lander; Gad Getz
Journal:  Nat Biotechnol       Date:  2013-02-10       Impact factor: 54.908

View more
  4 in total

1.  Experimental models of undifferentiated pleomorphic sarcoma and malignant peripheral nerve sheath tumor.

Authors:  Angela D Bhalla; Sharon M Landers; Anand K Singh; Jace P Landry; Michelle G Yeagley; Gabryella S B Myerson; Cristian B Delgado-Baez; Stephanie Dunnand; Theresa Nguyen; Xiaoyan Ma; Svetlana Bolshakov; Brian A Menegaz; Salah-Eddine Lamhamedi-Cherradi; Xizeng Mao; Xingzhi Song; Alexander J Lazar; Ian E McCutcheon; John M Slopis; Joseph A Ludwig; Dina C Lev; Kunal Rai; Keila E Torres
Journal:  Lab Invest       Date:  2022-02-28       Impact factor: 5.662

2.  CDX2 expression in malignant peripheral nerve sheath tumour: a potential diagnostic pitfall associated with PRC2 inactivation.

Authors:  Olumide O Odeyemi; Michael G Ozawa; Gregory W Charville
Journal:  Histopathology       Date:  2022-02-28       Impact factor: 7.778

3.  High enhancer activity is an epigenetic feature of HPV negative atypical head and neck squamous cell carcinoma.

Authors:  S Carson Callahan; Veena Kochat; Zhiyi Liu; Ayush T Raman; Margarita Divenko; Jonathan Schulz; Christopher J Terranova; Archit K Ghosh; Ming Tang; Faye M Johnson; Jing Wang; Heath D Skinner; Curtis R Pickering; Jeffrey N Myers; Kunal Rai
Journal:  Front Cell Dev Biol       Date:  2022-07-19

4.  Loss of H3K27me3 expression in canine nerve sheath tumors.

Authors:  Kristina Tekavec; Tanja Švara; Tanja Knific; Jernej Mlakar; Mitja Gombač; Carlo Cantile
Journal:  Front Vet Sci       Date:  2022-07-29
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.